Subtype
Esophageal Carcinoma
CI-CAN-00002609ESCAExplore in graph →
307 active trials4 approved drugs11 evidence items
- NCIt
- C3513
- DOID
- 1107
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002609ESCAExplore in graph →
Clinical trials
807 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (62)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy(SKYSCRAPER-07) | completed | Phase 3 | 760 | Hoffmann-La RocheINDUSTRY | 28 | Sep 14, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT07488624 | Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma | completed | — | 414 | Sichuan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06281886 | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 170 | Sun Yat-sen UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | completed | Phase 3 | 703 | Merck Sharp & Dohme LLCINDUSTRY | 27 | Jul 22, 2026 | clinicaltrials |
| NCT07705412 | Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | completed | — | 465 | Tongji HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | completed | Phase 3 | 203 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04183218 | Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes | completed | — | 24 | Mayo ClinicOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT02606396 | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | completed | N/A | 15 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT03322267 | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | completed | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07416825 | Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19 | completed | N/A | 23 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05142709 | Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC. | completed | — | 1,197 | Fudan UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07363629 | Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial | completed | N/A | 120 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT01618643 | Aceto-whitening in the Assessment of Gastrointestinal Neoplasia | completed | — | 197 | Portsmouth Hospitals NHS TrustOTHER_GOV | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04974047 | Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma(RATIONALE-213) | completed | Phase 2 | 70 | BeiGeneINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07236320 | Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC | completed | N/A | 200 | Yongtao HanOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04408105 | Survey Study on Barrett's Esophagus Screening(SCREEN-BE) | completed | — | 725 | University of Colorado, DenverOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03819088 | Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer | completed | N/A | 17 | Emory UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT05051475 | Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus(RATE) | completed | N/A | 62 | Centre of Postgraduate Medical EducationOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06192212 | PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy | completed | — | 577 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07201571 | A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea | completed | — | 3,131 | Samsung Medical CenterOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06333665 | PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy | completed | — | 605 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07182266 | Perioperative Outcomes and Survival of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy for Selected Esophageal Cancer | completed | — | 1,661 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07181850 | Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features(pCR-ESCC) | completed | — | 363 | Nanjing Medical UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05880082 | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer(PPIO-004-EC001) | completed | Phase 2 | 118 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT03797625 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | completed | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT06048913 | Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | completed | Phase 2 | 56 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06030180 | CLUE: CLinical Utility Study of EsoGuard(PR-0410) | completed | N/A | 566 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT04548440 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | completed | Phase 2 | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 | 37 | National Cancer Center, JapanOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 | 17 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT05524844 | The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE) | completed | — | 54 | Columbia UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials